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Abstract
Background—Radiation pneumonitis is a dose-limiting toxicity for patients undergoing
concurrent chemoradiation therapy (CCRT) for non-small cell lung cancer (NSCLC). We
performed an individual patient data meta-analysis to determine factors predictive of clinically
significant pneumonitis.
Methods—After a systematic review of the literature, data was obtained on 836 patients who
underwent CCRT in Europe, North America and Asia. Patients were randomly divided into
training and validation sets (2/3 vs. 1/3 of patients). Factors predictive of symptomatic
pneumonitis (grade ≥ 2 by one of several scoring systems) or fatal pneumonitis were evaluated
using logistic regression. Recursive partitioning analysis (RPA) was used to define risk groups.
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Results—The median radiotherapy dose was 60 Gy, and median follow-up was 2.3 years. Most
patients received concurrent cisplatin/etoposide (38%) or carboplatin/paclitaxel (26%). The
overall rate of symptomatic pneumonitis was 29.8% (n=249), with fatal pneumonitis in 1.9%
(n=16). In the training set, factors predictive of symptomatic pneumonitis were lung volume
receiving ≥20 Gy (V20) [OR:1.03 per 1% increase, p=0.008], and carboplatin/paclitaxel
chemotherapy [OR:3.33, p<0.001], with a trend for age [OR: 1.24 per decade, p=0.09]; the model
remained predictive in the validation set with good discrimination in both datasets (c-
statistic>0.65). On RPA, the highest risk of pneumonitis (>50%) was in patients >65 years of age
receiving carboplatin/paclitaxel. Predictors of fatal pneumonitis were daily dose >2 Gy, V20, and
lower-lobe tumor location.
Conclusions—Several treatment-related risk factors predict the development of symptomatic
pneumonitis, and elderly patients who undergo CCRT with carboplatin-paclitaxel chemotherapy
are at highest risk. Fatal pneumonitis, although uncommon, is related to dosimetric factors and
tumor location.
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INTRODUCTION
Concurrent chemoradiotherapy (CCRT) is the standard of care in patients presenting with a
locally advanced non-small cell lung cancer (NSCLC), as the role of surgery in patients with
documented mediastinal nodal disease remains controversial (1). Compared to sequential
chemotherapy and radiation therapy, CCRT results in improved survival outcomes, at the
cost of increased acute toxicity (1). Currently, a number of different radiation schedules and
chemotherapy combinations are in clinical use for CCRT.
Symptomatic radiation pneumonitis is a clinically important toxicity, occurring in 15–40%
of patients receiving CCRT for NSCLC (2). The risk of pneumonitis limits the radiotherapy
dose that can be safely delivered and the size of the volumes treated. Radiation pneumonitis
can limit quality of life, and uncommonly result in oxygen dependence or death (2).
Several studies have identified relationships between baseline patient- or dose-related
factors and rates of radiation pneumonitis (2), but predictive models have not been widely
implemented for several reasons: many earlier studies included heterogeneous groups of
patients not necessarily applicable to modern NSCLC treatment (i.e. patients treated without
chemotherapy, with older radiotherapy techniques, or for non-lung malignancies);
correlations between baseline variables and pneumonitis outcomes are generally weak; and
results are rarely validated in separate datasets (2, 3). As a result, the ability of a physician to
predict the risk of clinically significant pneumonitis for any particular patient is limited.
Recently, the Quantitative Analysis of Normal Tissue Effects in Clinic (QUANTEC) project
reviewed more than 70 published articles to provide normal-tissue dose constraints for
radiation-induced lung injury (4). Due to inconsistent relationships between patient- and
treatment-related factors and pneumonitis risk, QUANTEC recommended the pooling of
individual patient data from many institutions to undertake meta-analyses in an effort to
overcome some of the limitations of previous studies. Consequently, we undertook a
collaborative project entitled “Systematic analysis of toxicity after radical irradiation:
pneumonitis and esophagitis” (STRIPE) to combine patient-level data from several
institutions worldwide. The goal of this first component of the STRIPE project was to
develop and validate a predictive model for radiation pneumonitis in patients receiving
modern CCRT for the treatment of locally-advanced NSCLC.
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A systematic review was conducted to identify articles published in MEDLINE between
1993 and August 2010 reporting on dosimetric predictors of radiation pneumonitis after
CCRT for non-small cell lung cancer. Reference lists from candidate articles were hand-
searched for additional articles, and international experts were individually contacted to
identify additional published or unpublished datasets. Authors were then contacted and
invited to submit datasets with individual patient data, whether published or unpublished.
The search strategy and results are shown in Online Appendix 1. Institutional Research
Ethics Board approval was obtained.
Patients were included in the analysis if they were treated with concurrent
chemoradiotherapy for NSCLC with radical intent. Patients who did not receive full-doses
of radiation due to the development of toxicity during treatment remained included. Two-
dimensional radiotherapy was not allowed; radiotherapy had to be delivered as three-
dimensional conformal radiation therapy or intensity modulated radiation therapy. Patients
who received either induction (or neoadjuvant, prior to CCRT) or adjuvant (after CCRT)
chemotherapy were permitted. Patients were excluded from the analysis if the histology was
small-cell lung cancer, if they had stage IV disease, or if they underwent surgical resection.
Patients were staged according to the American Joint Committee on Cancer (AJCC) sixth
edition.
The primary endpoint of this study was symptomatic radiation pneumonitis, defined as:
Grade 2 or higher as per the Common Terminology Criteria for Adverse Events [CTC-AE]
version 3.0 (i.e. symptomatic), and/or requiring steroids. In individual datasets, the scoring
systems used including CTC-AE versions 2 and 3, the Radiation Therapy and Oncology
Group (RTOG) scale, the Southwest Oncology Group scale, and two in-house scales. In
each of these scoring systems, any patient scored as having Grade ≥2 pneumonitis
equivalent was scored as meeting the primary endpoint in this current study. The timing of
pneumonitis was not widely available; therefore actuarial rates were not reported.
The volume of lung considered as the organ at risk (OAR) was defined as the total lung
volume minus the gross tumor volume [i.e. total lung – GTV]. For patients whose V20 data
was only available using the definition of lung OAR as total lung minus planning target
volume [i.e. total lung – PTV], the corresponding “total lung – GTV” values were calculated
by imputation based on a linear relationship between the two definitions, which was found
to be a good fit with r=0.988. The resulting equation for V20 was: V20(lung-GTV)
=3.02528 + 1.00823*V20(lung-PTV); indicating that a patient with a V20 of 30% using the
lung-PTV definition would have a V20 of 33.3% using the lung-GTV definition; a similar
imputation was done for mean lung dose (MLD). Six patients had only data with the lung
OAR defined as the total lung volume minus clinical target volume [i.e. total lung – CTV],
and these patients were excluded as there was insufficient data for imputation. Performance
status was scored by different institutions using either the Eastern Cooperative Oncology
Group (ECOG) scale or the Karnofsky Performance Scale (KPS). In order to combine these
into a single variable, patients were classified patients as having “Good performance status”
(ECOG 0–1 or KPS 70–100) or “Poor performance status” (ECOG >1 or KPS <70).
For the endpoint of symptomatic pneumonitis, patients were randomly divided into a
training set (two-thirds of patients) and a validation set (one-third of patients) using a
random number generator, without stratification. In the training set, logistic regression was
used to determine factors predictive of pneumonitis. Any variables associated with the
development of pneumonitis on univariable analysis (with a cutoff alpha of 0.10) with data
available for at least two-thirds of patients were considered for entry into a stepwise
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multivariable model with entry and removal allowed at the 10% level of significance. Data
was required on two-thirds of patients since patients with missing data are excluded from
multivariable logistic modeling. The performance of the multivariable model was then
evaluated using the validation set.
A recursive partitioning analysis (RPA) was then constructed in the training set to stratify
patients into risk groups. This RPA is independent of the multivariable analysis described
above. The classification method of recursive partitioning was used, with a minimum
number of observations per node of 20 before a split was considered, and a default number
of minimum observations of 7 in a terminal node. This RPA stratification was then re-tested
on the validation set. RPA was done independently of the multivariable analysis. RPA
cutoffs were rounded to increase clinical utility.
For the endpoint of fatal pneumonitis, there were insufficient numbers of events to allow for
modeling with a training and validation set, and therefore the dataset was analyzed as a
whole. For this endpoint, logistic regression was used for continuous variables and Fisher’s
exact test used for categorical variables.
Survival estimates were calculated using the Kaplan-Meier method, and median follow-up
was calculated using the reverse Kaplan-Meier estimate. All statistical tests were two-sided
with a p≤0.05 indicative of statistical significance, done using SAS 9.2 (Cary, North
Carolina, USA) or R 2.13 (Vienna, Austria).
RESULTS
Data was available on 836 patients from 12 different sources (Table 1), all previously
reported in whole or in part, including 10 manuscripts (3, 5–13) and 2 abstracts (14, 15),
some of which provided updated datasets. The final composite dataset included patients
treated at centers in Europe (n=297, 36%), North America (n=286, 34%) and Asia (n=253,
30%). Baseline clinical characteristics are shown in Table 2. The median total dose
delivered was 60 Gy, most often in fractionated doses of 2 Gy per day (73%), 1.8 Gy per
day (13%) or 1.2 Gy twice daily (8%). Median follow-up was 2.3 years. There were 415
deaths in the cohort during the follow-up period, with a median overall survival (OS) of 1.7
years, 2-year OS of 44% and 5-year OS of 22%. The overall rate of symptomatic
pneumonitis was 29.8% (n=249).
Most patients received concurrent cisplatin/etoposide (38%) or carboplatin/paclitaxel (26%).
‘Other’ chemotherapy regimens included: cisplatin doublets (24%) [with docetaxel (11%),
vinorelbine (7%), gemcitabine (2%) or other drugs (4%)], carboplatin doublets (5%), or
gemcitabine (6%). Elderly patients (age >65) were more likely to receive ‘other’ types of
chemotherapy (delivered to 43% of elderly patients vs. 32% of younger patients; p=0.02),
corresponding to less use of cisplatin-etoposide in elderly patients (32% vs. 42%,
respectively), with similar rates of use of carboplatin-paclitaxel (25% vs. 26%, respectively).
Results from the univariable analysis and multivariable analysis on the training dataset
(n=557) are shown in Table 3. On multivariable analysis, factors predictive of development
of radiation pneumonitis were V20 [odds ratio (OR) 1.03 per 1% increase in V20, p=0.008],
chemotherapy regimen [OR for carboplatin/paclitaxel 3.33, relative to cisplatin-etoposide;
p<0.001], and with a trend toward significance for advanced age [OR per 10-yr increase
1.24, 95% CI 0.97–1.59, p=0.09]. The c-statistic for this model was 0.66, indicating good
discrimination.
Assessment of the model on the validation set (n=279) is shown in Table 4, with very
similar results as in the training set: chemotherapy and V20 significantly predicted
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pneumonitis risk (both p<0.001) with a trend toward significance for age (p=0.089), with
similar ORs as in the training set, and the c-statistic of 0.69 confirmed good discrimination.
The risk of pneumonitis based on cutoffs of V20 for the whole cohort combined is shown in
Table 5.
Results of the STRIPE recursive partitioning analysis are shown in Figure 1. Based on
chemotherapy regimen, age>65, V20, and MLD, patients can be divided into a high-risk
group (patients >65 years of age receiving carboplatin-paclitaxel); two intermediate-risk
groups; and two low-risk groups. The differences in pneumonitis rates between these groups
was statistically significant (p<0.001). Application of the categories formed by the RPA to
the validation set was consistent with those by the training data set. There was a strong
correlation (r2=0.902) between the pneumonitis rates in the training and validation sets in
each of the risk categories, and the differences in pneumonitis rates between the risk groups
remained statistically significant.
Fatal pneumonitis occurred in sixteen patients (1.9%), an insufficient number to allow for
detailed modeling with a training and validation set, or construction of a RPA model, and
therefore the dataset was analyzed as a whole. Total daily dose greater than 2 Gy (7% if >2
Gy vs. 1.5% if ≤ 2Gy; p=0.01), V20 (OR 1.09 per 1% increase, p=0.044), and tumor location
(1% for upper lobe, 0% for middle lobe, and 5% for lower lobe, p=0.007) were found to be
associated with fatal pneumonitis.
DISCUSSION
The onset of radiation pneumonitis after radical CCRT for NSCLC is associated with
significant morbidity and occasionally mortality. To our knowledge, this is the largest study
evaluating predictors of radiation pneumonitis following CCRT for lung cancer; it is one of
very few studies employing separate training and validation datasets; and importantly it
identifies several treatment-related variables that can be used to optimize the therapeutic
ratio in patients undergoing CCRT. A key finding is the suggestion that age, dosimetric
parameters, and choice of chemotherapy regimen can allow for significant stratification of
radiation pneumonitis risk. Although fatal pneumonitis isuncommon, it was associated with
large daily doses, high V20 values, and lower-lobe tumors. As a result, efforts to minimize
V20 and fraction size are warranted in the setting of concurrent CCRT.
The findings of this study are congruent with the existing literature regarding pneumonitis
risk, and extend those findings in several important ways. Increasing age and delivery of
concurrent taxane-based chemotherapy have been separately identified as risk factors for
radiation pneumonitis (4, 16, 17). Taxanes are potent radiosensitizers when given
concurrently with radiotherapy (16, 17). A recent study of a cohort of lung cancer patients
predominantly treated with carboplatin-paclitaxel CCRT found that both chemotherapy use
and age were associated with large increases in pneumonitis risk: the incidence of
pneumonitis in patients receiving chemotherapy was 63% (vs. 16% in patients not receiving
chemotherapy) with a trend toward increased risk in patients receiving carboplatin-paclitaxel
specifically. Pneumonitis occurred in 77% of patients aged 61–70, with lower rates in
patients of different ages (16). These data support the finding that the choice of
chemotherapy regimen plays an important role in pneumonitis risk, particularly in the
elderly.
Several chemotherapy regimens are available for concurrent CCRT, and the choice of
chemotherapy regimen is the subject of some controversy. Several platinum-based
chemotherapy regimens have demonstrated encouraging clinical outcomes (1). In the
context of palliative chemotherapy, a meta-analysis has demonstrated that cisplatin is a more
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active first-line treatment against NSCLC than carboplatin: cisplatin achieves superior
response rates, and in some subgroups improved survival (18).. The carboplatin-paclitaxel
CCRT combination has been compared in a 3-arm randomized non-inferiority study against
irinotecan-carboplatin and mitomycin-vindesine-cisplatin, with the latter considered the
“standard” arm (19). All three arms received 60 Gy of radiation, but the “standard” arm
incorporated split-course radiotherapy. Although survival outcomes were similar in all 3
arms, the non-inferiority endpoint was not met. Grade 3 or higher pneumonitis rates were
not statistically different between the arms, whereas rates of grade 2 pneumonitis, or rates in
elderly patients, were not reported. The National Comprehensive Cancer Network (NCCN)
clinical practice guidelines recommend cisplatin-etoposide as the chemotherapy of choice
for CCRT, with carboplatin-paclitaxel reserved for patients unable to tolerate full-dose
cisplatin (1)., Although efficacy is of primary importance in choosing a chemotherapy
regimen, avoidance of toxicity should also be a consideration.
The findings of this study must be considered in the context of its strengths and limitations.
The large sample size that incorporates data from several institutions worldwide improves
statistical power and the generalizability of the results, and the results have been validated in
a separate dataset. However, several important limitations must be borne in mind. Adequate
data was not available on some variables of interest, such as smoking status, co-morbidities,
pulmonary function, and timing of radiation pneumonitis symptoms, and some data required
imputation, which may have added a degree of imprecision. Some factors were not routinely
captured at most institutions, including baseline patient factors (e.g. pulmonary function),
biological factors (e.g. transforming growth factor beta levels), or more detailed dosimetric
factors (e.g. normal tissue complication probabilities), which have been previously
suggested as a predictors of pneumonitis risk (2). Individual-level chemotherapy dosing was
generally not available. There may also be differences between patients treated at different
institutions that have not been captured, including differences in genetic risks of
pneumonitis, treatment factors, or follow-up practices. Some of these unmeasured factors
could have influenced the final results. These findings described may not be generalizable to
patients with baseline characteristics or treatment parameters that differ from the population
included herein, such as the patients aged>75, who are a minority of the patients included.
These limitations underscore the importance of developing multi-institutional databases that
can be populated prospectively, to allow for the construction of more detailed prediction
models. Despite these limitations, the data presented here showing strata of risk based on
V20, MLD, and other clinical factors will allow clinicians to better predict and modify risk
in patients undergoing CCRT.
The overall rates of radiation pneumonitis reported herein are in keeping with previously
published CCRT studies, usually ranging between 15–40% for similar patient populations
(2). One study of radiation dose escalation in combination with carboplatin-paclitaxel
(RTOG 0117) reported a maximum tolerated dose of 74 Gy in 37 fractions in patients with a
V20 ≤ 30%; at this dose level 33% of patients developed grade 2 or higher pulmonary
toxicity. At a higher dose level (75.25 Gy in 35 fractions), 6/8 patients developed pulmonary
toxicity, illustrating the dose-limiting effects of radiation pneumonitis (20). However,
comparisons of pneumonitis rates across studies are limited by heterogeneity in patient
populations, treatment, and outcome scoring.
Several previous studies have reported correlations between radiation dosimetric parameters
and pneumonitis. V20 and MLD are frequently correlated with pneumonitis and are most
commonly used in clinical practice, yet other variables have been shown to be predictive,
including volume of lung receiving ≥5 Gy (V5), ≥13 Gy (V13), ≥25 Gy (V25) and ≥30 Gy
(V30) (2). However, dosimetric variables tend to be very collinear (i.e. increasing V20 tends
to lead to an increase in the other parameters), and therefore differences in predictive value
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among different dosimetric variables may be small. The relative merit of decreasing one
dosimetric variable (e.g. lowering the V20) at the expense of another (e.g. raising the V5) is
unknown.
In conclusion, this study suggests that in patients undergoing concurrent chemoradiation
therapy for NSCLC, pneumonitis risk is associated with the type of chemotherapy regimen,
dosimetric parameters, and patient age. Fatal pneumonitis is uncommon, but is associated
with large doses per fraction, large V20, and lower-lobe tumors. Further research is needed
to evaluate methods to mitigate pneumonitis risk in patients undergoing curative-intent
CCRT.
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Radiation pneumonitis is a dose-limiting toxicity for patients undergoing concurrent
chemoradiation therapy (CCRT) for non-small cell lung cancer. This individual-patient
data meta-analysis demonstrated that several treatment-related risk factors predict the
development of symptomatic pneumonitis, and elderly patients who undergo CCRT with
carboplatin-paclitaxel chemotherapy are at highest risk. Fatal pneumonitis was
uncommon, but related to dosimetric factors and tumor location.
Palma et al. Page 9











Recursive partitioning analysis of radiation pneumonitis risk in patients undergoing
concurrent chemoradiation therapy (CCRT) for non-small cell lung cancer (NSCLC).
Patients were randomly divided into a training set (T) and validation set (V). MLD: mean
lung dose; V20: volume of lung receiving ≥ 20 Gy.
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Table 1
Sources of individual patient data
Institution Number of Patients
Hyogo Medical Center, Japan 190
Indiana University School of Medicine, Indianapolis, USA 98
VU University Medical Center, Amsterdam, Netherlands 84
Pulmonart Multicenter Study 68
University of Pennsylvania, Philadelphia, USA 68
University of Navarra, Pamplona, Spain 67
Washington University School of Medicine, St. Louis, USA 64
National Cancer Center, Goyang, Korea 63
Campus Bio-Medico University, Rome, Italy 51
Duke University, Durham, USA 33
Karolinska University Hospital, Stockholm, Sweden 27
London Regional Cancer Program, London, Canada 23
Total 836
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Table 2
Baseline clinical characteristics.
Variable N with data available Median (Range) or number (%)
Age 836 63 (26–86)
Sex 836
 Male 603 (72%)
 Female 233 (28%)
Good Performance Status* 396 382 (96%)
Smoking History 511 462 (55%)
Histology 525
 Adenocarcinoma 155 (30%)
 Large Cell 58 (11%)
 Squamous 212 (40%)
 NSCLC NOS 100 (19%)
Tumor Lobe Location 487
 Upper 327 (67%)
 Middle 25 (5%)
 Lower 135 (28%)
Tumor stage 836
 TX 36 (4%)
 T1 90 (11%)
 T2 245 (29%)
 T3 196 (23%)
 T4 269 (32%)
Nodal Stage 836
 NX 26 (3%)
 N0 48 (6%)
 N1 38 (5%)
 N2 488 (58%)
 N3 236 (28%)
Stage Grouping 836
 IB 1 (0.1%)
 II 11 (1.3%)
 III 824 (98.6%)
Neoadjuvant Chemotherapy 531 296 (56%)
Concurrent Chemotherapy 836 836 (100%)
Concurrent Chemotherapy Agents 633
 Cisplatin-Etoposide 243 (38%)
 Carboplatin-Paclitaxel 164 (26%)
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Variable N with data available Median (Range) or number (%)
 Other** 226 (36%)
Adjuvant Chemotherapy 498 116 (23%)
Prescribed Radiation Dose (Gy) 834 60 (36–84)
Dose Per Fraction (Gy) 796 2 (1.2–2.15)
Lung volume receiving ≥5 Gy (%) 404 38 (14–100)
Lung volume receiving ≥20 Gy (%) 819 30 (7–78)
Mean Lung Dose (Gy) 759 17 (2–47)
IQR: interquartile range; NSCLC: non-small cell lung cancer; NOS: not otherwise specified
*
defined as Eastern Cooperative Oncology Group Performance Status of 0–1 or Karnofsky performance status of ≥70.
**
see text for details.
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Table 4
Multivariable analysis of factors predictive of symptomatics radiation pneumonitis in the validation dataset
(n=279).
Factor Multivariable Analysis
OR 95% CI p-value
Age (per 10 yr increase) 1.38 0.95–2.01 .089
Chemotherapy Regimen <0.001
 Cisplatin- Etoposide 1 -Reference-
 Carboplatin- paclitaxel 5.52 2.25–13.55
 Other 3.39 1.50–7.68
Volume of lung receiving ≥20 Gy(V20) 1.07 1.03–1.11 <.001
OR: odds ratio; CI: confidence interval.
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Table 5
Risk of radiation pneumonitis based on V20 (volume of lung receiving 20 Gy or more) in the whole cohort of
patients (training and validation set combined).
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